Prices delayed by at least 15 minutes | Print
Shield Therapeutics PLC (STX)
ORD 1.5POpen
2p
Previous close
2p
Trade high
2.05p
Volume
632,383
Year high
12.85p
Year low
1.90p
Dividend yield
-
Market capitalisation
£15.84 mn
P/E ratio
32.15
ISIN
GB00BYV81293
This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segmentsare based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.
News
Recent trades
Date | Time | Price | Quantity | Value (£) |
---|---|---|---|---|
28/03/2024 | 04:22:53 | 2.049 | 4,500 | 92.21 |
28/03/2024 | 03:40:24 | 2.05 | 200 | 4.10 |
28/03/2024 | 03:40:24 | 2.05 | 487 | 9.98 |
28/03/2024 | 03:36:16 | 2.03 | 30,000 | 609.00 |
28/03/2024 | 03:33:59 | 1.9854 | 4,357 | 86.50 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.